[Correspondence] Olanzapine for chemotherapy-induced nausea and vomiting control – Authors’ reply

April, 04, 2024 | Select Oncology Journal Articles

We thank Venkatraman Radhakrishnan and colleagues, Vinod Sharma and colleagues, and Seiji Tsuruta and colleagues for their interest in our study of low-dose olanzapine.1 In response to concerns about the rationale for assuming a 5% higher total chemotherapy-induced nausea and vomiting control in the low-dose group than in the standard-dose group, it should be noted that the efficacy of any treatment is not only a function of its on-target efficacy but a composite outcome of several factors, including treatment compliance, which is toxicity dependent.

For Additional News from OncWeekly – Your Front Row Seat To The Future of Cancer Care –




Sign up for our emails

Trusted insights straight to your inbox and get the latest updates from OncWeekly

Privacy Policy